New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
16:02 EDTBSTC, AUXLBioSpecifics announces filing by Sobi for EU approval of XIAPEX
BioSpecifics Technologies (BSTC) announced today that Swedish Orphan Biovitrum AB, or Sobi, has filed for an extension of the label for XIAPEX with the European Medicines Agency to include the indication of Peyronie's disease. XIAPEX is currently approved for the treatment of Dupuytren's contracture in adult patients with a palpable cord. BioSpecifics' partner, Auxilium Pharmaceuticals (AUXL), is partnered with Sobi for the marketing of XIAPEX in 71 Eurasian and African countries for the treatment of Dupuytren's contracture, and Peyronie's disease pending applicable regulatory approvals.
News For BSTC;AUXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
08:13 EDTAUXL, BSTCBioSpecifics announces FDA approval of sBLA for XIAFLEX
Subscribe for More Information
October 20, 2014
17:33 EDTAUXLAuxilium announces XIAFLEX approved for treatment of up to two DC joints
Subscribe for More Information
October 16, 2014
08:41 EDTBSTCBioSpecifics' CCH shows positive preclinical results for uterine fibroid tumors
Subscribe for More Information
October 13, 2014
06:41 EDTAUXLEndo upgraded to Hold from Sell at Cantor
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use